Member Info for johndean

EMV Capital plc announced a significant commercial update for its portfolio company AMR Bio, highlighting the advancement of its XF-73 asset towards Phase 3 clinical trials for preventing post-surgical infections. Following EMV Capital's acquisition of the XF-73 assets and a £1.3 million funding round, AMR Bio has established a dedicated management team and secured regulatory advantages including FDA Fast Track status and UK MHRA Accelerated Access. The XF-73 Nasal program, which previously demonstrated a 99.5% reduction in bacterial carriage in a Phase 2b study, is now preparing for FDA guidance for Phase 3, alongside exploring a dermal application for wound infections. The company estimates potential peak sales of up to $1 billion annually for XF-73 in specific surgical procedures.

Volkswagen has filed a legal challenge against the UK Financial Conduct Authority's proposed £9b car finance redress scheme.

The company is seeking independent clarification on how compensation rules should apply to its historical car finance agreements.

The case has potential financial implications for Volkswagen and may influence how auto finance complaints are handled across the sector.

For shareholders, this legal move comes at a time when Volkswagen, XTRA:VOW3, is already under pressure in the market. The share price stands at €85.48, with returns showing a 19.7% decline year to date and a 39.1% decline over five years. This backdrop makes any large, uncertain liability especially important to watch.

Looking ahead, the court process around the FCA scheme is likely to be lengthy and closely followed by the market. Investors may pay particular attention to any guidance on potential cost ranges, timing of cash outflows, and whether other manufacturers face similar exposure, as these factors could influence sentiment toward XTRA:VOW3 and the wider auto finance space.

Disappointed with barc and lloy

Barclays PLC has decided not to join the lenders challenging the UK Financial Conduct Authority's GBP9 billion compensation scheme for the motor finance scandal, Sky News reported on Friday.

The London-based bank joins Lloyds Banking Group PLC in deciding not to challenge the FCA's ruling, the regulator having confirmed in March that millions of motorists are in line for compensation for being mis-sold a car finance agreement between 2007 and 2024.

Firms are expected to pay out compensation totalling around GBP7.5 billion, down from a previous estimate of GBP8.2 billion, with the total bill rising to GBP9.1 billion when including the cost of running the scheme.

"Sky News has learnt that Barclays decided on Friday not to challenge the [ruling]," the outlet said.

Sky had previously reported that the Finance & Leasing Association was leaning towards challenging the FCA over the proposed scheme, and could announce its board's decision "as early as Sunday."

A group of other lenders are still preparing to take legal action against the FCA ahead of a Monday deadline.

Sky added that "Santander Consumer Finance, an arm of the Spanish banking giant, is said to still be deliberating over the issue."

(Sharecast News) - The Finance & Leasing Association is reportedly preparing for a legal challenge against the Financial Conduct Authority's motor finance compensation scheme announced last month.

According to Sky News, the trade body - whose members provided £55bn to help consumers buy cars last year - was expected to announce the outcome of its deliberations with members as soon as Sunday.

One source told Sky that a legal challenge to the FCA's £9.1bn redress scheme was now "overwhelmingly likely", barring any last-minute hitches.

If confirmed, the decision does not necessarily mean that all FLA members will participate in the legal action. Some, including Santander Consumer Finance are understood to still have been holding their own internal discussions this week about whether to participate in any coordinated industry-wide challenge.

It emerged last week that Lloyds Banking Group had decided not to pursue a legal challenge despite having provisioned close to £2bn for consumer redress payments.

"While we remain disappointed in and disagree with [the FCA's] conclusions, we believe that moving forward with the scheme is now the right step for our customers and shareholders in support of a clear, orderly and final process that provides certainty for consumers and industry," Lloyds told the Financial Times.

Under FCA rules, any legal challenge must be brought within 28 days of a redress scheme being launched, meaning that Monday is the deadline for the FLA and other lenders.

FLA members include Santander and the finance arms of automotive groups such as BMW and Volkswagen.

Rookie, youre the terrorist,and please learn to spell

Worryingly hl still not online

Anyone else having problems with hl

AFC Energy Plc reported a loss after tax of £22.2 million for the financial year ended 31 October 2025, an increase from the previous year's £17.4 million loss, primarily due to increased R&D investment of £11.7 million and non-cash expenditures including stock and debtor write-offs totaling £8.4 million. The company successfully raised £27.5 million gross in July 2025 to accelerate commercial development and product deployment, ending the year with £25.3 million in cash and short-term investments. Key operational highlights include the launch of the new LC30 fuel cell generator and progress on the Hy-5 ammonia cracker, with the company targeting £10/kg for hydrogen sales. Post-period, a joint development agreement was signed with Komatsu Ltd, and an environmental permit was secured, allowing for earlier hydrogen production revenue.

It went up yesterday, because of this news, its just we get to hear about it later

Ferdinand, is rio your first name, stick to football pls

Avacta Group PLC announced that experimental data for its pre|CISION mechanism, specifically FAP-Exd (AVA6103), demonstrates significant advantages over the marketed antibody drug conjugate Enhertu®, including more rapid tumor penetration, a one log higher absolute maximum drug concentration in the tumor, and a nearly three-fold higher Tumor Selectivity Index. The company expects to initiate a Phase 1 clinical trial for AVA6103 in Q1 2026, with the AI-driven analysis supporting increased confidence in the program's success.

Close X

Renalytix plc reported unaudited revenues of $1.6 million for the first half of fiscal year 2026, with full-year revenue guidance now projected at approximately $4 million, representing a 33% year-over-year increase. The company successfully implemented three new electronic medical record integrations in the first half, with more expected in the second half, and is planning a large-scale hospital group integration involving a 1,000-patient pilot. Renalytix is also advancing a real-world evidence study to validate and expand the utility of its kidneyintelX.dkd product, which is expected to be integrated into up to five additional healthcare organizations' EMR systems. Furthermore, the relocation of laboratory operations is anticipated to deliver over $1 million in operating cost savings over five years, while the company maintained a cash balance of approximately $6 million as of December 31, 2025.

Aptamer Group plc announced that Twist Bioscience Corporation has launched its new TrueAmp Library Preparation Kit, which incorporates Aptamer's proprietary Optimer® binders as an enabling technology for room temperature stability. This partnership, stemming from a non-exclusive license agreement signed in December 2025, strategically combines Twist Bioscience's synthetic biology expertise with Aptamer's Optimer® technology to enhance the rapidly expanding next-generation sequencing market. The TrueAmp kit aims to deliver exceptional performance, high yields from low-input or degraded samples, and streamline large-scale workflows, demonstrating the real-world value of Aptamer's technology in market-ready products.

Shot up 8% any ideas why?

Haydale Graphene Industries PLC has successfully completed the acquisition of SaveMoneyCutCarbon (SMCC) and raised approximately £5.75 million in gross proceeds through a fundraising. This acquisition is considered a transformational step, creating a scalable, graphene-enabled clean-tech platform with immediate market access, integrating SMCC's customer acquisition engine and B2B delivery platform with Haydale's advanced materials and technologies like JustHeat. The enlarged group is now positioned to address the growing demand for decarbonisation solutions in the built environment, with integration of SMCC underway and SMCC's CEO joining the board as Chief Commercial Officer.

Renalytix plc announced the successful completion of three new kidneyintelX.dkd clinical integrations in the United States during the last quarter of 2025, with initial testing volumes now active at these sites. The company is also advancing its collaboration with Tempus AI, Inc. to enhance electronic health record integration and data collection, aiming for future data-driven kidney disease solutions. The CEO is attending the J.P. Morgan Healthcare Conference to engage with investors, and the company expects to provide further updates on progress and trading in February 2026.

With hl still not rec dividend,anyone else in same position

sold out after that **** presentation

What a waste of time,watching this .